These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. Iida O; Nanto S; Uematsu M; Morozumi T; Kitakaze M; Nagata S J Vasc Surg; 2008 Jul; 48(1):144-9. PubMed ID: 18482817 [TBL] [Abstract][Full Text] [Related]
8. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Tanabe Y; Ito E; Nakagawa I; Suzuki K Int J Cardiol; 2001 May; 78(3):285-91. PubMed ID: 11376832 [TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting. Takeyasu N; Watanabe S; Noguchi Y; Ishikawa K; Fumikura Y; Yamaguchi I Circ J; 2005 Jul; 69(7):780-5. PubMed ID: 15988102 [TBL] [Abstract][Full Text] [Related]
10. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S; J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668 [TBL] [Abstract][Full Text] [Related]
11. Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis. Tomoi Y; Soga Y; Iida O; Fujihara M; Ando K J Endovasc Ther; 2017 Oct; 24(5):640-646. PubMed ID: 28675951 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Lee SW; Chun KJ; Park SW; Kim HS; Kim YH; Yun SC; Kim WJ; Lee JY; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Jon S; Cho YH; Lee NH; Kim JH; Park SJ Am J Cardiol; 2010 Jan; 105(2):168-73. PubMed ID: 20102913 [TBL] [Abstract][Full Text] [Related]
13. Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS. Tsuchikane E; Takeda Y; Nasu K; Awata N; Kobayashi T Catheter Cardiovasc Interv; 2004 Sep; 63(1):44-51. PubMed ID: 15343566 [TBL] [Abstract][Full Text] [Related]
14. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676 [TBL] [Abstract][Full Text] [Related]
15. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Kim HS; Ko JK; Park JH; Lee JH; Choi SW; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Park SJ J Am Coll Cardiol; 2008 Mar; 51(12):1181-7. PubMed ID: 18355656 [TBL] [Abstract][Full Text] [Related]
16. RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. Ge J; Han Y; Jiang H; Sun B; Chen J; Zhang S; Du Z; J Cardiovasc Pharmacol; 2005 Aug; 46(2):162-6. PubMed ID: 16044027 [TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial. Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828 [TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ; J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640 [TBL] [Abstract][Full Text] [Related]
20. Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Yoon Y; Shim WH; Lee DH; Pyun WB; Kim IJ; Jang Y; Cho SY Am J Cardiol; 1999 Dec; 84(12):1375-80. PubMed ID: 10606107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]